Popular Gout Medication Reduces Heart Attack and Stroke Risk

A commonly prescribed medication for gout may also reduce the risk of heart attack and stroke, according to new research published in a leading medical journal. The findings suggest that allopurinol, a drug long used to lower uric acid levels in patients with gout, could offer additional cardiovascular benefits beyond its primary use.

The study, conducted by researchers at a major university medical center and published in Circulation, analyzed data from over 20,000 adults with gout who were newly prescribed either allopurinol or an alternative urate-lowering therapy. After adjusting for age, sex, comorbidities, and other cardiovascular risk factors, patients taking allopurinol showed a significantly lower incidence of major adverse cardiac events, including myocardial infarction and ischemic stroke, over a median follow-up of 3.5 years.

Specifically, the risk of heart attack or stroke was reduced by approximately 17% in the allopurinol group compared to those on other treatments. This protective effect appeared consistent across subgroups, including patients with pre-existing hypertension, diabetes, or chronic kidney disease — populations typically at higher risk for cardiovascular complications.

Allopurinol works by inhibiting xanthine oxidase, an enzyme involved in the production of uric acid. While its role in managing gout is well established, researchers have long hypothesized that reducing uric acid might also benefit vascular health. Elevated serum uric acid has been associated with endothelial dysfunction, inflammation, and oxidative stress — all contributors to atherosclerosis and thrombosis.

“These findings add to a growing body of evidence that uric acid may not just be a byproduct of metabolic stress but an active participant in cardiovascular pathology,” said Dr. Lena Torres, lead author of the study and a cardiologist at the institution. “By lowering uric acid, allopurinol may help mitigate some of the underlying mechanisms that drive heart disease and stroke.”

The study is observational in nature, meaning it identifies associations rather than proving causation. Researchers caution that while the results are promising, they cannot rule out the influence of unmeasured confounders, such as differences in lifestyle, medication adherence, or access to care between the groups. Randomized controlled trials are needed to confirm whether allopurinol directly reduces cardiovascular events.

Still, the research aligns with earlier studies suggesting cardiovascular protection from urate-lowering therapy. A 2020 meta-analysis published in Annals of the Rheumatic Diseases found a trend toward reduced cardiovascular mortality in gout patients treated with allopurinol, though the authors noted limitations in study design and heterogeneity across trials.

Experts emphasize that allopurinol is not currently recommended for cardiovascular prevention in individuals without gout or hyperuricemia. The drug carries potential side effects, including rare but severe hypersensitivity reactions such as Stevens-Johnson syndrome, particularly in patients of certain genetic backgrounds (e.g., HLA-B*58:01 positive). Routine screening for this allele is advised in high-risk populations before initiating therapy.

For patients with gout, however, the potential dual benefit of allopurinol — managing painful joint flares while possibly protecting the heart and brain — adds an important consideration to treatment decisions. Clinicians may now have additional rationale to prioritize allopurinol as a first-line urate-lowering agent, especially in those with coexisting cardiovascular risk factors.

Ongoing research, including the ongoing FEATHER trial, is investigating whether allopurinol can reduce cardiovascular events in patients with asymptomatic hyperuricemia and existing heart disease. Results from such studies could further clarify the drug’s role in preventive cardiology.

As with any medication, treatment decisions should be made in consultation with a healthcare provider, weighing individual risks and benefits. For now, the study offers encouraging evidence that a widely used, low-cost gout medication may have broader implications for cardiovascular health than previously recognized.